Creatine Kinase, Exertional Rhabdomyolysis, and Exercise-Associated Hyponatremia in Ultra-Endurance Athletes: A Critically Appraised Paper
Clinical Scenario
Exercise-associated muscle damage results in elevated plasma creatine kinase (CK), often diagnosed as exertional rhabdomyolysis (ER) in runners. Likewise, exercise-associated hyponatremia (EAH) is prevalent in ultra-endurance racers. A link has been proposed between ER and EAH in that the simultaneous presentation of EAH and ER creates a complicated and opposing treatment paradox regarding fluid resuscitation.
Focused Clinical Question
What is the relationship between EAH and ER in ultra-endurance athletes? 
Search Strategy

Evidence Quality Assessment
This investigation utilized a multiple-group, non-randomized, cohort-control research design, or a Level 2b according OCEBM. The STROBE statement was used to assess the quality of this study, which met 19/22 of the criteria.
Study Patients and Sampling. Subjects were 113 ultra-endurance athletes participating in a variety of ultra-events (ultra-mountain bikers: stage racers and 24-hr ultra-bikers; ultra-runners: 24-hr ultra-and 100-km ultra-runners). The study included 6 race finishers with rhabdomyolysis as diagnosed by blood CK levels >10,000 U/L without the development of renal failure or necessity of medical treatment.
Control Group. The control group consisted of 100 normonatremic ultra-athletes who completed their respective event and provided a complete data set of blood and urine samples. Of the normonatremic finishers, 4 (4 %) ultra-runners (all men) developed ER.
Experimental Group. The researchers found 13 hyponatremic athletes diagnosed with postrace plasma [Na+] <135 mmol/L with 2 (15.4 %, one man and one woman) who developed ER.
Outcome Measures. Athletes agreed to provide blood and urine measurements during registration the day before each race and upon completion of the race. Blood samples were analyzed for plasma [Na+] , [K+] , CK, and urine creatinine; only CK and [Na+] are reported here.
Clinical Bottom Line(s)
1. Of the ultra-endurance race finishers in this study (n=113), 5.3% developed ER with CK >10,000 U/L and 15.9 % developed ER/myopathy (CK >2,000 U/L). Of the ultra-runners, 28.6% (6/21) developed ER and none of the ultra-mountain bikers. Hyponatremic ultraathletes developed ER more often than normonatremic ultra-athletes. 2. Due to the wide inter-individual ranges of CK and the excessively high CK in asymptomatic ultra-athletes, the value of CK as a prognostic or diagnostic tool is questionable. 3. In situations where the diagnosis of EAH is uncertain, treatment with fluid restriction is contraindicated in case of dehydration and ER which may lead to acute kidney injury.
Implications for Practice, Education, and Future Research
The overall incidence rate of ER was 5.3% (6/113) in ultra-endurance race finishers and 28.6% (6/21) of ultra-runners. Ultra-athletes who developed ER had an average post-race CK= 18,423.6±6,138.8 U/L (range= 12,786.2-29,702.9 U/L). These ranges for post-race CK far exceed the 5-10 times upper limit of normal for CK for diagnosis of ER, indeed these athletes had 9,659.0±8,793.3% (2,665.0±26,209.0%) increased CK from baseline. Further, the ultrarunners who did not present with ER also reported with exceedingly high CK, but were asymptomatic. The table below was calculated in aggregate from the data provided by the researchers and includes the plasma [Na+] and CK averages, ranges, and % change from baseline for all ultra-race finishers. In the EAH and ER group, post-race CK increased 7,160.3±6,238.4% (2,749.0±11,571.5%) from pre-race while in the ER only group post-race CK increased 10,908.4±10,471% (2,665.0-26,209 .0) from pre-race. In all the ultra-runners (n=21) CK increased 3,365.8±4,098.7% (990.7-5,782.1%) from pre-race while in all the mountain bikers (n=82) CK increased 458.9±511.3% (308.1-590.9%) from pre-race. The total finished ultra-marathons, total hours spent training weekly, and gender were related to post-race CK concentration (P >0.05) in both groups.
Comments:
The major strengths of this investigation were external validity or the generalizability of the sample of the large variety of ultra-endurance events and the number and quality of the variables assessed. Fortunately, none of the ultra-runners who developed ER required medical intervention. The major limitation of this investigation was the small sample size for the athletes who developed ER, as expected with the low incidence rate of this condition in well-trained athletes. Furthermore, the investigators did not confirm the presence of myoglobinuria, although this clinical indicator is less sensitive and not clinically useful. Finally, following the subjects for an additional 24-72 hr would have likely demonstrated increased CK, a reliable clinical indicator of more severe rhabdomyolysis.
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